Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov) - Jul 26, 2024 - P1 | N=40 | Not yet recruiting | Sponsor: Plus Therapeutics | Trial completion date: Jan 2025 ➔ Mar 2028 | Trial primary completion date: Jan 2025 ➔ Mar 2028
Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|